Since October 2010, the US Food and Drug Administration (FDA) has approved 3 new anticoagulants that, for the first time, offer patients with such conditions as stroke in the setting of atrial fibrillation (AF), deep vein thrombosis, and pulmonary embolism a long-awaited alternative to the vitamin K antagonist warfarin. This new class of drugs, called […]
Continue reading about The New Anticoagulants: Indications and Risks
Sedation overuse is frequent and possibly associated with poor outcomes in the intensive care unit (ICU) patients. However, the association of early oversedation with clinical outcomes has not been thoroughly evaluated. The aim of this study was to assess the association of early sedation strategies with outcomes of critically ill adult patients under mechanical ventilation […]
Per la prima volta dopo il 2006, il Nice inglese ha aggiornato le Linee Guida per il trattamento dell’aritmia più diffusa, la fibrillazione atriale. Vengono così inclusi anche i nuovi anticoagulanti orali, che diventano opzione alternativa di prima linea alla terapia standard con antagonisti della vitamina K. Atrial fibrillation: the management of atrial fibrillation
Continue reading about Il Nice aggiorna le linee guida per la fibrillazione atriale